Viewing nowCombinationNexgliptin Duo Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.

MFDS item code 202200117 · Approved 2022.01.06 · Insurance code 643105750
Improvement of blood glucose control in patients with type 2 diabetes mellitus
This medicine is used as an adjunct to help control blood sugar in patients with type 2 diabetes. It is administered when blood sugar control is difficult with dietary and exercise therapy, and is especially effective in cases where patients have not previously received diabetes medication or where monotherapy is insufficient. It can be used as a substitute when blood glucose control is not achieved with either metformin or sitagliptin monotherapy, or with combinations of these two medications. Additionally, if the effect is inadequate with the combination of metformin and sulfonylurea, or metformin and thiazolidinedione, this medicine can be used in conjunction. If blood sugar control remains difficult after combining insulin and metformin, this medicine can be used in combination with insulin. Thus, it is used to improve blood glucose control in patients with type 2 diabetes who are difficult to manage through multiple treatment methods.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2. Patients who must not take this medicine under Precautions for Use). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see section 5. General Precautions under Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Patients who must not take this medicine under Precautions for Use).
This medication may cause hypersensitivity reactions; if symptoms of allergy, skin rash, or difficulty breathing occur, discontinue use immediately and consult a doctor. Also, if symptoms of acute pancreatitis such as severe abdominal pain, nausea, or vomiting appear, cease medication immediately and inform healthcare personnel. This drug should not be used in patients with moderate or severe renal impairment or in states at risk of acute kidney failure, and kidney function should be regularly monitored for normalcy. Administration should also be avoided in patients with acute or unstable heart failure, severe infections, cardiovascular collapse, and in cases where iodine contrast agents are used during certain tests. It is advised not to use this medication during pregnancy or in women of childbearing potential, as well as in nursing mothers. Patients with irregular meals, malnutrition, engaging in vigorous exercise, or those using other medications that may cause hypoglycemia should exercise caution. This drug can cause a rare but serious side effect called lactic acidosis, so if symptoms like muscle pain, weakness, difficulty breathing, or abdominal pain occur, contact healthcare personnel immediately. Additionally, excessive alcohol consumption may increase the risk of lactic acidosis, so it is best to avoid. Due to the risk of hypoglycemia, the changes in blood sugar should be closely monitored when using this medication in conjunction with blood sugar-lowering agents or insulin, and the dosage of other medications should be adjusted if necessary. Before and after surgery, this medication should be discontinued for a certain period, resuming only after the patient's condition has stabilized and kidney function is confirmed to be normal. Routine blood tests and kidney function checks should be conducted while on this medication, and periodic checks of vitamin B12 levels are recommended. If blisters or rash appear on the skin, inform a doctor immediately, and precaution should be taken in cases of severe joint or muscle pain. This medication is not used in children and adolescents as its safety and efficacy have not been confirmed. In the case of overdose, inform healthcare personnel immediately and receive appropriate treatment, including blood dialysis if necessary.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it is best stored at room temperature, between 1 and 30 degrees Celsius, avoiding extremes of heat or cold.
Pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.